INFINITI BRAF Assay
Sample Type and Volume:
- BRAF mutations are present in about 12% of carcinomas
- Common in the following cancers:
- Mutations may indicate prognosis and drug response to Cancer therapies (anti-EGFR drugs – Cetuximab/Erbitux, Panitumumab/Vectibix, Gefitinib/Iressa, Erlotinib/Tarceva).
- Identification of BRAF mutations suggests that anti-EGFR therapies will not work in most, if not all patients.
- Presence of BRAF mutations also suggests prognosis for Thyroid cancer and Melanomas.
- Garnett MJ, Marais R (2004). "Guilty as charged: B-Raf is a human oncogene". Cancer Cell 6 (4): 313–9. doi:10.1016/j.ccr.2004.09.022. PMID 15488754.
- Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005). "Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations". Cancer 103 (11): 2261–8. doi:10.1002/cncr.21073. PMID 15880523.